Bill Maughan
Stock Analyst at Canaccord Genuity
(1.42)
# 2,421
Out of 4,412 analysts
13
Total ratings
11.11%
Success rate
-0.95%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Buy | $15 → $16 | $6.87 | +132.90% | 1 | Mar 26, 2024 | |
| BNTX BioNTech SE | Reiterates: Buy | $171 | $87.21 | +96.08% | 4 | Mar 21, 2024 | |
| IPSC Century Therapeutics | Maintains: Buy | $22 → $24 | $2.88 | +733.33% | 1 | Mar 15, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $22 → $26 | $14.71 | +76.75% | 1 | Mar 4, 2024 | |
| IMCR Immunocore Holdings | Maintains: Hold | $60 → $63 | $58.46 | +7.77% | 2 | Feb 29, 2024 | |
| MRNA Moderna | Maintains: Hold | $82 → $91 | $107.97 | -15.72% | 2 | Feb 23, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $60 | $22.71 | +164.20% | 1 | Feb 21, 2024 | |
| MRUS Merus | Initiates: Buy | $45 | $45.04 | -0.09% | 1 | Nov 2, 2023 |
Nkarta
Mar 26, 2024
Maintains: Buy
Price Target: $15 → $16
Current: $6.87
Upside: +132.90%
BioNTech SE
Mar 21, 2024
Reiterates: Buy
Price Target: $171
Current: $87.21
Upside: +96.08%
Century Therapeutics
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $2.88
Upside: +733.33%
Y-mAbs Therapeutics
Mar 4, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $14.71
Upside: +76.75%
Immunocore Holdings
Feb 29, 2024
Maintains: Hold
Price Target: $60 → $63
Current: $58.46
Upside: +7.77%
Moderna
Feb 23, 2024
Maintains: Hold
Price Target: $82 → $91
Current: $107.97
Upside: -15.72%
Bicycle Therapeutics
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $22.71
Upside: +164.20%
Merus
Nov 2, 2023
Initiates: Buy
Price Target: $45
Current: $45.04
Upside: -0.09%